Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 21, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Submits Investigational New Drug Application for NasoVAX in Preparation for Phase 2 Trial

60 volunteers to be enrolled Data expected in the first quarter of 2018 GAITHERSBURG, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics...
August 17, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Announces $14.7 Million Series B Preferred Stock Offering

GAITHERSBURG, Md., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a definitive securities purchase...
August 10, 2017 00:24 ET | Source: Altimmune, Inc.

Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update

Completed merger with PharmAthene, began trading on NASDAQ as Altimmune, Inc. (ALT) Remains on track to initiate Phase 2 trial in NasoVAX in Third Quarter HepTcell Phase 1 clinical trial ongoing in...
July 31, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune to Announce Second Quarter 2017 Financial Results on August 10

GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the three...
June 19, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune to Provide Corporate Update at the BIO International Convention

GAITHERSBURG, Md., June 19, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive...
May 16, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer

GAITHERSBURG, Md., May 16, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced the promotion of Sybil Tasker, M.D., FACP, FIDSA, to...
May 04, 2017 16:01 ET | Source: Altimmune, Inc.

Altimmune Completes Merger with PharmAthene Creating Immunotherapeutics Company Targeting Infectious Diseases

GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT) announced today the completion of its merger with PharmAthene, Inc., effective May 4, 2017. Upon the completion of...
April 26, 2017 16:01 ET | Source: Altimmune, Inc.

PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market

ANNAPOLIS, Md. and GAITHERSBURG, Md., April 26, 2017 (GLOBE NEWSWIRE) -- As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company...
March 28, 2017 08:00 ET | Source: Altimmune, Inc.

Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™

GAITHERSBURG, Md., March 28, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutics company, today announced that the Company was awarded a contract modification to their...
December 06, 2016 09:50 ET | Source: Altimmune, Inc.

UPDATE -- Altimmune Announces Acceptance of HepTcell Abstract for Presentation at BSI/NVVI Congress 2016

GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect...